Flipping the treatment order could change the game for brain metastases. A new retrospective study found that delivering radiation before surgery activates immune pathways typically suppressed in brain tumors, boosting T-cell diversity and potentially making tumors more responsive to immunotherapy. Researchers say this could be a key step toward improving survival for patients whose brain metastases have resisted conventional treatment.
Flipping the treatment order could change the game for brain metastases
An estimated 10–30% of adults with cancer develop brain metastases, with a median survival of less than 6 months. A major hurdle has been the brain's immunologically "cold" tumor microenvironment, which blunts the effectiveness of immunotherapy. Now, a retrospective study from MD Anderson Cancer Center suggests a promising workaround: delivering radiation before surgery rather than after.
Researchers analyzed tissue samples from 306 patients with brain metastases from lung or breast cancer, plus 91 participants in an ongoing prospective trial. They found that preoperative ionizing radiation enhanced T-cell receptor (TCR) diversity, upregulated antigen presentation, and activated immune signatures typically suppressed in the brain — essentially "warming up" the tumor microenvironment and potentially priming it for immunotherapy like immune checkpoint inhibitors.
Key Takeaways:
Why it matters: Brain metastases are increasingly the "final frontier" as systemic therapies better control peripheral disease. If preoperative radiation can reliably prime the immune microenvironment, combining it with checkpoint inhibitors could meaningfully extend survival — a strategy already being planned for larger prospective trials.
